한글목차

도파민 작용제 시장 규모는 최근 현저하게 확대하고 있습니다. 2025년 27억 3,000만 달러에서 2026년에는 29억 3,000만 달러로, CAGR 7.3%로 성장할 것으로 예상됩니다. 지난 수년간의 성장은 파킨슨병 유병률 증가, 도파민 치료의 초기 임상적 성공, 운동장애에 대한 대체요법의 제한적 선택, 신경과 진료센터 확대, 진단율 향상 등에 기인하는 것으로 보입니다.

도파민 작용제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 38억 6,000만 달러에 달하고, CAGR은 7.1%가 될 전망입니다. 예측 기간 동안의 성장 요인으로는 전 세계 고령화, 신경질환 부담 증가, 운동 증상 조절 개선에 대한 수요, 재택 신경 의료의 확대, 환자 친화적인 제제 개발 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 파킨슨병 치료에서의 사용 증가, 비맥각계 도파민 작용제 채택 확대, 지속형 제제 선호도 증가, 경피 투여 옵션 확대, 하지 가려움증 증후군에서의 사용률 증가 등을 꼽을 수 있습니다.

신경 질환의 유병률 증가는 도파민 작용제 시장의 성장을 견인할 것으로 예상됩니다. 신경질환은 뇌, 척수, 신경에 영향을 미쳐 운동기능, 인지기능, 행동에 장애를 일으키는 질환군입니다. 이러한 유병률 상승의 한 요인은 평균 수명의 연장에 있으며, 알츠하이머병, 파킨슨병 등의 발병 위험은 나이가 들수록 높아집니다. 도파민 작용제는 뇌의 도파민 수용체를 자극하여 운동 조절을 강화하고 증상을 완화시켜 파킨슨병과 같은 신경 질환을 관리하는 데 사용됩니다. 예를 들어, 알츠하이머병 치료, 지원 및 연구에 전념하는 미국 비영리단체 알츠하이머병 협회의 보고서 '알츠하이머병의 사실과 수치'에 따르면, 2022년 65세 이상 미국인 650만 명이 알츠하이머병 진단을 받았으며, 2024년에는 690만 명으로 늘어날 것으로 예상하고 있습니다. 따라서 신경질환의 유병률 증가는 도파민 작용제 시장의 확대를 촉진할 것으로 예상됩니다.

도파민 작용제 시장에서 활동하는 주요 기업들은 환자의 복약 순응도를 높이고, 부작용을 최소화하며, 신경 질환에 대한 보다 개인화된 치료 옵션을 제공하기 위해 유연한 용량의 단일제 요법과 같은 혁신에 중점을 두고 있습니다. 유연한 용량의 단일제 요법은 용량을 조절할 수 있는 단일 약물을 사용하는 치료법으로, 의사가 각 환자의 특정 필요와 반응에 따라 용량을 맞춤화할 수 있는 치료 접근법입니다. 예를 들어, 2024년 12월, 미국에 본사를 둔 바이오제약 기업 애브비는 임상 3상 TEMPO-2 시험의 양호한 결과를 보고했습니다. 이에 따르면, 개발 중인 타바파돈(유연한 용량의 단일요법 : 1일 1회 5-15mg)은 초기 파킨슨병 환자의 운동기능을 유의하게 개선하는 것으로 나타났습니다. 본 임상시험은 주요 평가항목인 MDS-UPDRS Part II 및 III 점수가 유의미하게 감소하고, 주요 부수적 평가항목도 달성했으며, 일상생활에서 운동기능이 유의미하게 개선된 것으로 나타났습니다. 타바파돈은 1일 1회 투여하는 파킨슨병 치료제로 평가받고 있는 최초의 D1/D5 부분 작용제입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Dopamine agonists are drugs that stimulate dopamine receptors in the brain, imitating the actions of natural dopamine. They are employed to treat conditions resulting from reduced dopamine activity or disrupted dopamine signaling.

The primary categories of dopamine agonists include ergot-based dopamine agonists and non-ergot-based dopamine agonists. Ergot-based dopamine agonists are drugs derived from ergot alkaloids that stimulate dopamine receptors in the brain to assist in managing neurological and hormonal disorders. They are available in multiple forms of administration, including oral, parenteral, and transdermal patches. These drugs are supplied through various distribution channels, such as hospital pharmacies, retail pharmacies, and other pharmacy outlets. They are utilized for several conditions, including Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia. The main end users consist of hospitals, clinics, and home care environments.

Tariffs have affected the dopamine agonists market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and specialized excipients used in neurological drugs. These impacts have been most pronounced in branded and transdermal segments, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific manufacturers have experienced pricing pressure and supply chain disruptions due to trade dependencies. However, tariffs have supported domestic API production and local formulation development, enhancing regional supply continuity.

The dopamine agonists market research report is one of a series of new reports from The Business Research Company that provides dopamine agonists market statistics, including dopamine agonists industry global market size, regional shares, competitors with a dopamine agonists market share, detailed dopamine agonists market segments, market trends and opportunities, and any further data you may need to thrive in the dopamine agonists industry. This dopamine agonists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dopamine agonists market size has grown strongly in recent years. It will grow from $2.73 billion in 2025 to $2.93 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of parkinson's disease, early clinical success of dopamine therapies, limited alternatives for movement disorders, expansion of neurology care centers, improved diagnostic rates.

The dopamine agonists market size is expected to see strong growth in the next few years. It will grow to $3.86 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to aging global population, rising neurological disorder burden, demand for improved motor symptom control, growth of home-based neurological care, development of patient-friendly formulations. Major trends in the forecast period include rising use in parkinson's disease management, growing adoption of non-ergot dopamine agonists, increased preference for long-acting formulations, expansion of transdermal delivery options, higher utilization in restless legs syndrome.

The increasing prevalence of neurological disorders is expected to drive the growth of the dopamine agonist market. Neurological disorders are medical conditions that impact the brain, spine, or nerves, leading to difficulties with movement, cognition, or behavior. This rising prevalence is partly attributed to longer life expectancies, as the likelihood of developing conditions such as Alzheimer's and Parkinson's increases with age. Dopamine agonists are used to manage neurological disorders like Parkinson's disease by stimulating dopamine receptors in the brain, enhancing motor control, and alleviating symptoms. For example, in 2024, according to the Alzheimer's Disease Facts and Figures report by the Alzheimer's Association, a US-based nonprofit organization dedicated to Alzheimer's care, support, and research, 6.5 million Americans aged 65 and older were diagnosed with Alzheimer's dementia in 2022, which rose to 6.9 million in 2024. Consequently, the growing prevalence of neurological disorders is anticipated to propel the expansion of the dopamine agonist market.

Major companies operating in the dopamine agonists market are emphasizing innovations such as flexible-dose monotherapy to enhance patient adherence, minimize side effects, and offer more personalized treatment options for neurological disorders. Flexible-dose monotherapy is a therapeutic approach that utilizes a single medication with adjustable dosing, enabling physicians to customize the dosage according to each patient's specific needs and response. For example, in December 2024, AbbVie Inc., a US-based biopharmaceutical company, reported positive topline results from its Phase 3 TEMPO-2 trial, showing that the investigational tavapadon, a flexible-dose monotherapy (5-15 mg once daily), significantly improved motor function in patients with early Parkinson's disease. The trial met its primary endpoint with a notable reduction in MDS-UPDRS Parts II and III scores and achieved key secondary endpoints, demonstrating meaningful improvement in daily motor activities. Tavapadon is the first D1/D5 partial agonist being evaluated for once-daily Parkinson's treatment.

In August 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired Cerevel Therapeutics for $8.7 billion. Through this acquisition, AbbVie intends to enhance its neuroscience portfolio by obtaining access to Cerevel Therapeutics' innovative pipeline of treatments for neurological and psychiatric disorders. Cerevel Therapeutics Holdings Inc. is a US-based biopharmaceutical company focused on developing therapies for psychiatric and neurological conditions.

Major companies operating in the dopamine agonists market are Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, Luye Pharma Group Ltd., Kissei Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Hetero Drugs Ltd., Mylan N.V., Sandoz Group AG, Hikma Pharmaceuticals PLC, Apotex Inc., Alkem Laboratories Ltd

North America was the largest region in the dopamine agonists market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dopamine agonists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dopamine agonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dopamine agonist market includes sales of pramipexole, ropinirole, rotigotine, apomorphine, bromocriptine, and cabergoline. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dopamine Agonists Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses dopamine agonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dopamine agonists ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dopamine agonists market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Ergot Based Dopamine Agonists; Non Ergot Based Dopamine Agonists
• 2) By Route of Administration: Oral; Parenteral; Transdermal Patches
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies
• 4) By Application: Parkinson's Disease; Restless Legs Syndrome (RLS); Hyperprolactinemia
• 5) By End User: Hospitals; Clinics; Home Care Settings
• Subsegments:
• 1) By Ergot-Based Dopamine Agonists: Bromocriptine; Cabergoline; Pergolide
• 2) By Non-Ergot-Based Dopamine Agonists: Pramipexole; Ropinirole; Rotigotine; Apomorphine
• Companies Mentioned: Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Intas Pharmaceuticals Ltd.; Dr. Reddy's Laboratories Ltd.; Lupin Limited; Luye Pharma Group Ltd.; Kissei Pharmaceutical Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited; Cipla Limited; Torrent Pharmaceuticals Ltd.; Zydus Lifesciences Ltd.; Glenmark Pharmaceuticals Ltd.; Alembic Pharmaceuticals Ltd.; Hetero Drugs Ltd.; Mylan N.V.; Sandoz Group AG; Hikma Pharmaceuticals PLC; Apotex Inc.; Alkem Laboratories Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Dopamine Agonists Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Dopamine Agonists Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Dopamine Agonists Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Dopamine Agonists Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Use In Parkinson'S Disease Management
  • 4.2.2 Growing Adoption Of Non-Ergot Dopamine Agonists
  • 4.2.3 Increased Preference For Long-Acting Formulations
  • 4.2.4 Expansion Of Transdermal Delivery Options
  • 4.2.5 Higher Utilization In Restless Legs Syndrome

5. Dopamine Agonists Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Neurology Clinics
• 5.3 Specialty Clinics
• 5.4 Home Care Settings
• 5.5 Rehabilitation Centers

6. Dopamine Agonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Dopamine Agonists Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Dopamine Agonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Dopamine Agonists Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Dopamine Agonists Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Dopamine Agonists Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Dopamine Agonists Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Dopamine Agonists Market Segmentation

• 9.1. Global Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ergot Based Dopamine Agonists, Non Ergot Based Dopamine Agonists
• 9.2. Global Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Parenteral, Transdermal Patches
• 9.3. Global Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
• 9.4. Global Dopamine Agonists Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Parkinson's Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia
• 9.5. Global Dopamine Agonists Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Home Care Settings
• 9.6. Global Dopamine Agonists Market, Sub-Segmentation Of Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Bromocriptine, Cabergoline, Pergolide
• 9.7. Global Dopamine Agonists Market, Sub-Segmentation Of Non Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pramipexole, Ropinirole, Rotigotine, Apomorphine

10. Dopamine Agonists Market Regional And Country Analysis

• 10.1. Global Dopamine Agonists Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Dopamine Agonists Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Dopamine Agonists Market

• 11.1. Asia-Pacific Dopamine Agonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Dopamine Agonists Market

• 12.1. China Dopamine Agonists Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Dopamine Agonists Market

• 13.1. India Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Dopamine Agonists Market

• 14.1. Japan Dopamine Agonists Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Dopamine Agonists Market

• 15.1. Australia Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Dopamine Agonists Market

• 16.1. Indonesia Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Dopamine Agonists Market

• 17.1. South Korea Dopamine Agonists Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Dopamine Agonists Market

• 18.1. Taiwan Dopamine Agonists Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Dopamine Agonists Market

• 19.1. South East Asia Dopamine Agonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Dopamine Agonists Market

• 20.1. Western Europe Dopamine Agonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Dopamine Agonists Market

• 21.1. UK Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Dopamine Agonists Market

• 22.1. Germany Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Dopamine Agonists Market

• 23.1. France Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Dopamine Agonists Market

• 24.1. Italy Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Dopamine Agonists Market

• 25.1. Spain Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Dopamine Agonists Market

• 26.1. Eastern Europe Dopamine Agonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Dopamine Agonists Market

• 27.1. Russia Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Dopamine Agonists Market

• 28.1. North America Dopamine Agonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Dopamine Agonists Market

• 29.1. USA Dopamine Agonists Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Dopamine Agonists Market

• 30.1. Canada Dopamine Agonists Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Dopamine Agonists Market

• 31.1. South America Dopamine Agonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Dopamine Agonists Market

• 32.1. Brazil Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Dopamine Agonists Market

• 33.1. Middle East Dopamine Agonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Dopamine Agonists Market

• 34.1. Africa Dopamine Agonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Dopamine Agonists Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Dopamine Agonists Market Regulatory and Investment Landscape

36. Dopamine Agonists Market Competitive Landscape And Company Profiles

• 36.1. Dopamine Agonists Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Dopamine Agonists Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Dopamine Agonists Market Company Profiles
  • 36.3.1. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Lupin Limited Overview, Products and Services, Strategy and Financial Analysis

37. Dopamine Agonists Market Other Major And Innovative Companies

• Luye Pharma Group Ltd., Kissei Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Hetero Drugs Ltd., Mylan N.V., Sandoz Group AG, Hikma Pharmaceuticals PLC, Apotex Inc., Alkem Laboratories Ltd

38. Global Dopamine Agonists Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Dopamine Agonists Market

40. Dopamine Agonists Market High Potential Countries, Segments and Strategies

• 40.1 Dopamine Agonists Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Dopamine Agonists Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Dopamine Agonists Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer